Although GLP-1 RA treatment reduced ROCK activation and hypertrophy in cultured cardiac myoblasts stimulated by angiotensin II [155], there are no available human data on the effect of GLP-1 RA on ROCK activation in patients with MS or T2D, and GLP-1 RA may reduce ROCK activation in PBMCs, as well as body weight, plasma glucose, and insulin levels; increase aerobic capacity; and possibly decrease left atrial volume while improving left atrial function, potentially preventing HF in patients with MS or T2D. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.